CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 6375474
• 负责人: DAVID D HURD
• 金额: $ 25.98万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-04-01 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6375474
• 关键词: AIDS related neoplasm /cancer; aging; antineoplastics; bone marrow transplantation; breast neoplasms; cancer prevention; cancer registry /resource; carmustine; chemoprevention; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; finasteride; fluorouracil; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human genetic material tag; human subject; human therapy evaluation; interleukin 2; leucovorin; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; oncology nursing; paclitaxel; pathology; prostate neoplasms; psychology; quality of life; respiratory neoplasm; tamoxifen; tissue resource /registry; weight loss

DESCRIPTION (adapted from the applicant's abstract): The Comprehensive Cancer Center of Wake Forest University continues to be a major accrue to Cancer and Leukemia Group B protocols. A modest decrease in accrual is noted for 1996 which reflects economic constraints and the influence of managed care. We have obtained an R13 CA-74441 demonstration grant to evaluate and strengthen the recruitment and retention of minorities in cancer clinical trials. Further, we are applying through CALGB for the minority initiative program to obtain data management support for East Carolina University. They have access to a large minority population in eastern North Carolina. The anticipation that first-line protocols for leukemia, lymphoma, and advanced breast cancer will soon be available should also strengthen our accrual in this grant period. Our institutional and CCOP accrual to protocol #9399 (chemotherapy prevention of prostate cancer with finasteride) is an expression of our ability to accrue large number of patients quickly to cancer control clinical trials. Dr. David Hurd, Chair of the Transplant committee and Dr. Electra Paskett, Chair of the Cancer Control committee provide strong scientific contributions to CALGB and further strengthen our accrual to clinical trials. Dr. Jim Atkins, Chairman of the Southeast Cancer Control Consortium (SCCC), is developing a strong regional program with increasing emphasis on the accrual of minorities to clinical trials. Our strong community outreach clinical trials program is focused to develop community techniques which will improve accrual to clinical trials. The development of multi-disciplinary affinity groups in breast, GI, GU, leukemia, lung, neuro-oncology, and oral head/neck cancer will also strengthen our institutional contributions to Cancer and Leukemia Group B.

描述（改编自申请人的摘要）：综合 维克森林大学癌症中心继续成为主要贡献者 癌症和白血病 B 组方案。 应计费用略有减少 1996 年指出，反映了经济限制和 管理式护理。 我们已获得 R13 CA-74441 示范补助金 评估并加强对少数群体的招募和保留 癌症临床试验。 此外，我们正在通过 CALGB 申请 少数族裔倡议计划以获得东部数据管理支持 卡罗莱纳大学。 他们可以接触到大量少数民族人口 北卡罗来纳州东部。 一线协议的预期 白血病、淋巴瘤和晚期乳腺癌很快就会出现 还加强了我们在此赠款期内的应计收益。 我们的机构和 CCOP 应计协议#9399（前列腺癌的化疗预防） 与非那雄胺）是我们积累大量 患者迅速进入癌症对照临床试验。 大卫·赫德博士，主席 移植委员会主席和癌症委员会主席 Electra Paskett 博士 控制委员会为 CALGB 和 进一步加强我们对临床试验的积累。 吉姆·阿特金斯博士，主席 东南癌症控制联盟 (SCCC) 正在开发强大的 区域方案越来越强调少数群体的利益 临床试验。 我们强大的社区外展临床试验计划是 专注于开发社区技术，以提高应计收益 临床试验。 多学科亲和团体的发展 乳腺癌、胃肠道癌、胃肠道癌、白血病、肺癌、神经肿瘤学和口腔头颈癌 还将加强我们对癌症和白血病的机构贡献 B组。